The primary mechanism of action of antiresorptive therapies involves interaction with what type of cells?

• A. Osteoblasts
• B. Chondrocytes
• C. Osteoclasts
• D. Mesenchymal stem cells

Answer: (C)

Antiresorptive therapies are designed to halt or slow down the process of bone resorption, which is primarily carried out by osteoclasts. These cells are responsible for the breakdown of bone tissue, and their activity is crucial in maintaining the balance between bone formation and bone resorption. When osteoclast activity is excessive, it can lead to conditions such as osteoporosis, where bone density is compromised.

Antiresorptive medications, such as bisphosphonates and denosumab, primarily target osteoclasts to inhibit their function and reduce bone loss. By interacting with osteoclasts, these therapies effectively decrease the rate of bone resorption, thereby helping to preserve or increase bone density in individuals at risk for fractures.

The other cell types mentioned do not play a direct role in the mechanism of action for antiresorptive therapies. Osteoblasts are involved in bone formation, chondrocytes in cartilage formation, and mesenchymal stem cells can differentiate into various cell types, including osteoblasts. However, the key action point for antiresorptive agents is specifically related to osteoclasts.